Amanta Healthcare's IPO launched at ₹126 and its shares reached ₹138 on the BSE today, providing investors with a listing gain of approximately 9.5%. The company manufactures generic medicines and medical devices. The ₹126 crore raised from the IPO will be used for new manufacturing lines and the expansion of its Steriport.
IPO Listing: Amanta Healthcare's IPO proved to be a hit with investors, launching at a price of ₹126 and rising to ₹138 on the BSE today. The company manufactures sterile liquid products and medical devices, which are exported to 21 countries. The ₹126 crore raised from the IPO will be primarily utilized for the expansion of the Steriport and new manufacturing lines in Kheda, Gujarat. The company's net profit reached ₹10.50 crore in FY2025, while its debt has also seen a consistent reduction.
Initial Listing Gain
Early in the trading session today, Amanta Healthcare's shares offered investors an initial profit of approximately 7%. Subsequently, the shares continued to climb, reaching ₹138 on the BSE. This resulted in a profit of approximately 9.52% for investors who participated in the IPO.
According to experts, this surge is attributed to the b response to the IPO and the company's robust business model. The initial jump in its shares reflects investor enthusiasm.
Utilization of Funds Raised Through IPO
Amanta Healthcare raised capital through an IPO of ₹126 crore. The subscription period for the IPO was from September 1 to September 3, 2025. The IPO received an overwhelming response from investors and was subscribed 82.60 times overall.
The funds raised through the IPO will be used by the company to strengthen its production infrastructure. ₹70 crore will be allocated to the Steriport located in Hariyala, Kheda, Gujarat, and ₹30.13 crore will be used to establish new manufacturing lines at SVP. The remaining amount will be utilized for the company's general corporate purposes.
Company Overview
Amanta Healthcare was established in 1994. The company manufactures sterile liquid products and also produces medical devices. It boasts a portfolio of over 45 generic products, which are sold nationwide through 320 distributors and stockists.
The company's products are also available internationally. They are registered in 19 countries, including Africa, Latin America, and the UK. In FY2025, its products were exported to 21 countries.
Company's Financial Performance
Amanta Healthcare's financial performance has strengthened over the past few years. The company incurred a net loss of ₹2.11 crore in FY2023. However, this loss was eliminated in the following fiscal year, FY2024, with the company achieving a net profit of ₹3.63 crore. In FY2025, this profit grew to ₹10.50 crore.
The company's total income has also been consistently increasing. In FY2025, the company's total income reached ₹276.09 crore, growing at a compound annual growth rate of 2%.
Debt and Reserve Status
The company's debt has been continuously decreasing. At the end of FY2023, its debt was ₹215.66 crore, which reduced to ₹205.23 crore by the end of FY2024 and further to ₹195.00 crore by the end of FY2025.
Additionally, the company's reserves and surplus have also seen consistent growth. It stood at ₹36.05 crore in FY2023, increased to ₹39.46 crore in FY2024, and further grew to ₹67.56 crore in FY2025.
